HIF1A and acute promyelocytic leukemia: In patients with acute promyelocytic leukemia (APL), the combination of HIF-1α inhibitors with differentiation-inducing agents such as all-trans retinoic acid (ATRA) or arsenic trioxide (ATO) may have synergistic effects on promoting myeloid cell differentiation and improving treatment outcomes69,70.